(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/224313 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/02* (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:
PCT/IB2024/054005

(22) International Filing Date:
24 April 2024 (24.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/461,480	24 April 2023 (24.04.2023)	US
63/464,404	05 May 2023 (05.05.2023)	US
63/465,218	09 May 2023 (09.05.2023)	US
63/468,634	24 May 2023 (24.05.2023)	US
63/526,661	13 July 2023 (13.07.2023)	US
63/528,509	24 July 2023 (24.07.2023)	US
63/529,919	31 July 2023 (31.07.2023)	US
63/538,210	13 September 2023 (13.09.2023)	US
63/597,622	09 November 2023 (09.11.2023)	US
63/559,491	29 February 2024 (29.02.2024)	US

(71) Applicant: **SANOFI** [FR/FR]; 46 Avenue de la Grande Armée, 75017 Paris (FR).

(72) Inventors: **ADAMSON, Peter**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **AMARA, Celine**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **BASSET, Alexandra**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **DEMERS, Brigitte**; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR). **DRAGANOV, Dobrin**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **FRAENKEL, Paula**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **JENSEN, Kyle**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **SIAK-LENG, Choi**; c/o Sanofi, Patent Department, 46 Avenue de la Grande Armée, 75017 Paris (FR). **VALENTE, Delphine**; c/o Sanofi, Patent Department, 46 Avenue de la Grande Armée, 75017 Paris (FR). **ZITI-LJAJIC, Samira**; c/o Sanofi, Patent Department, 46 Avenue de la Grande Armée, 75017 Paris (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: USE OF CD123 NK CELL ENGAGER FOR TREATING AML AND RELATED DISORDERS

(57) Abstract: Provided herein are methods comprising multifunctional binding proteins comprising a first and a second antigen binding domain and all or part of an immunoglobulin Fc region or variant thereof, wherein the first antigen binding domain binds specifically to CD123 and the second antigen binding domain binds specifically to human NKp46, and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor, for the treatment or prevention of leukemias and myelodysplastic disorders.

WO 2024/224313 A1